#London #United Kingdom #FAMAR Group #MiP Pharma #PharmaVentures

PharmaVentures Leads Successful Sale of MiP Pharma’s Sterile Production Facility to FAMAR Group

London, June 5, 2025 — In a significant development in the pharmaceutical services sector, PharmaVentures has announced that it acted as the exclusive M&A advisor to capiton AG on the successful sale of MiP Pharma's sterile production facility located in Homburg, Germany, to FAMAR Group. This transaction not only marks a key milestone for capiton AG but also strengthens FAMAR's supply chain as it seeks to meet the growing demands of pharmaceutical services.

Since capiton AG took ownership of the MiP facility, it has undergone substantial transformations, turning it into a state-of-the-art manufacturing site recognized for its high standards. The sale of this facility is seen as pivotal in FAMAR's strategic expansion plans, providing them with access to advanced manufacturing capabilities and additional space for growth.

The Importance of M&A in Pharmaceutical Services

The pharmaceutical services industry, which encompasses Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs), and specialist consultancies, continues to evolve rapidly. Transactions such as this one are crucial drivers of growth in the pharmaceutical sector. With an increasing number of mergers and acquisitions, the landscape is changing, signaling a robust period of consolidation and strategic positioning within the industry.

Soren Demin, Head of M&A at PharmaVentures, expressed satisfaction over facilitating the divestment of MiP's manufacturing site. He noted, "This transaction aligns perfectly with MiP's strategic objectives, as it provides FAMAR with a world-class facility that has room for further development."

Dr. Fintan Walton, CEO and Founder of PharmaVentures, emphasized the impact that specialized advisors have in such transformative deals. He stated, "Our decades of experience in M&A, coupled with our extensive knowledge of the pharmaceutical services domain, empowers us to negotiate optimal deals for our clients."

About the Companies Involved

Capiton AG is distinguished as an independent, owner-managed private equity firm with a robust fund volume amounting to €1.6 billion. The firm is known for its active investment portfolio that encompasses 18 medium-sized companies, with a focus on management buy-outs and funding for growth in established businesses.

On the other hand, PharmaVentures has established itself as a leading advisory firm specializing in transactions within the pharmaceutical sector for over three decades. They have worked on more than 1000 deal-related projects which include mergers, acquisitions, licensing, and strategic alliances across the globe. Their expertise not only lies in deal structuring but also in market access and valuation insights which are critical for companies aiming to establish successful partnerships in the pharmaceutical arena.

This recent transaction serves as a testament to PharmaVentures’ capability in steering complex negotiations successfully, while substantially enhancing the operational potential of major players in the industry. As the demand for pharmaceuticals continues to grow, strategic moves such as these are set to shape the future landscape of pharmaceutical services globally.

Looking Forward

The integration of MiP's enhanced capabilities into FAMAR's operations is expected to significantly bolster FAMAR's service offerings, thereby enabling it to meet the ever-increasing market demands for pharmaceutical production services effectively. As they navigate this new chapter, the implications of this agreement could potentially pave the way for further advancements within the pharmaceutical services sector.

For more information about this transaction and PharmaVentures’ services, please visit PharmaVentures Website.